User:Aiswarya.m.r/sandbox

Paracetamol From Wikipedia, the free encyclopedia Paracetamol Paracetamol-skeletal.svg Paracetamol-from-xtal-3D-balls.png Systematic (IUPAC) name N-(4-hydroxyphenyl)ethanamide N-(4-hydroxyphenyl)acetamide Clinical data Trade names	Tylenol (USA), Anacin Aspirin Free (USA), Apra (USA), Crocin (India), Aeknil (India), Feverall (USA), Genapap (USA), Panadol (UK), Panadol (Australia/New Zealand), Panodil (Denmark), Efferalgan (France), Doliprane (France) Dafalgan (France) Alvedon (Sweden) AHFS/Drugs.com	monograph MedlinePlus	a681004 Licence data	US FDA:link Pregnancy cat. A (AU) C (US) Not tested but seems to be safe Legal status	Unscheduled (AU) GSL (UK) OTC (US) Routes	Oral, rectal, intravenous Pharmacokinetic data Bioavailability	~100% Metabolism	90 to 95% Hepatic Half-life	1–4 h Excretion	Renal Identifiers CAS number	103-90-2 Yes ATC code	N02BE01 PubChem	CID 1983 DrugBank	DB00316 ChemSpider	1906 Yes UNII	362O9ITL9D Yes KEGG	D00217 Yes ChEBI	CHEBI:46195 Yes ChEMBL	CHEMBL112 Yes PDB ligand ID	TYL (PDBe, RCSB PDB) Chemical data Formula	C8H9NO2 Mol. mass	151.163 g/mol SMILES[show] InChI[show] Physical data Density	1.263 g/cm³ Melt. point	169 °C (336 °F) [2][3] Solubility in water	12.78[1] mg/mL (20 °C) Yes (what is this?) (verify) Paracetamol (/ˌpærəˈsiːtəmɒl/ or /ˌpærəˈsɛtəmɒl/), acetaminophen Listeni/əˌsiːtəˈmɪnəfɨn/, or APAP, chemically named N-acetyl-p-aminophenol, is a widely used over-the-counter analgesic (pain reliever) and antipyretic (fever reducer).[4][5] Paracetamol is the International Nonproprietary Name (INN), Australian Approved Name (AAN) and British Approved Name (BAN), while acetaminophen is the United States Adopted Name (USAN) and Japanese Adopted Name (JAN).[6][7][8]

Paracetamol is classified as a mild analgesic. It is commonly used for the relief of headaches and other minor aches and pains and is a major ingredient in numerous cold and flu remedies. In combination with opioid analgesics, paracetamol can also be used in the management of more severe pain such as post-surgical pain and providing palliative care in advanced cancer patients.[9] Though paracetamol is used to treat inflammatory pain, it is not generally classified as an NSAID because it exhibits only weak anti-inflammatory activity.

While generally safe for use at recommended doses even small overdoses can be fatal. Compared to other over-the-counter pain relievers, paracetamol is significantly more toxic in overdose but may be less toxic when used chronically at recommended doses.[10] Paracetamol is the active metabolite of phenacetin and acetanilide, two once popular as analgesics and antipyretics in their own right.[11][12] However, unlike phenacetin, acetanilide and their combinations, paracetamol is not considered carcinogenic at therapeutic doses.[13]

The words acetaminophen (used in the United States,[7] Canada,[7] Japan)[6] and paracetamol (used elsewhere) both come from a chemical name for the compound: para-acetylaminophenol and para-acetylaminophenol. In some contexts, it is simply abbreviated as APAP, for acetyl-para-aminophenol. It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.[14]

Contents [hide] 1 Medical uses 1.1 Fever 1.2 Pain 2 Adverse effects 2.1 Liver damage 2.2 Cancer 2.3 Skin reactions 2.4 Asthma 2.5 Other factors 2.6 Overdose 2.7 Pregnancy 3 Mechanism of action 4 Structure and reactivity 5 Synthesis 6 Metabolism 7 Reactions 8 History 9 Available forms 10 Veterinary use 10.1 Cats 10.2 Dogs 10.3 Snakes 11 Controversy 12 Classification 13 References 14 External links Medical uses[edit] Fever[edit] Paracetamol is approved for reducing fever in people of all ages.[15] The World Health Organization (WHO) recommends that paracetamol only be used to treat fever in children if their temperature is greater than 38.5 °C (101.3 °F).[16] The efficacy of paracetamol by itself in children with fevers has been questioned[17] and a meta-analysis showed that it is less effective than ibuprofen.[18]

Pain[edit] Paracetamol is used for the relief of pains associated with many parts of the body. It has analgesic properties comparable to those of aspirin, while its anti-inflammatory effects are weaker. It is better tolerated than aspirin in patients in whom excessive gastric acid secretion or prolongation of bleeding time may be a concern. Available without a prescription since 1959,[19] it has since become a common household drug.[20]

Paracetamol has a relatively little anti-inflammatory activity, unlike other common analgesics such as the NSAIDs aspirin and ibuprofen, but ibuprofen and paracetamol have similar effects in the treatment of headache. Paracetamol can relieve pain in mild arthritis, but has no effect on the underlying inflammation, redness, and swelling of the joint.[21]

Regarding comparative efficacy, studies show conflicting results when compared to NSAIDs. A randomised controlled trial of chronic pain from osteoarthritis in adults found similar benefit from paracetamol and ibuprofen.[22][23]

The efficacy of paracetamol when used in combination with weak opioids (such as codeine) was assessed in data studies in 1996 and 2009,[24][25] which found improved efficacy for approximately 50% of patients but increases in the number of patients experiencing adverse effects. Combination drugs of paracetamol and strong opioids like morphine reduce the amount of opioid needed and improve analgesic effect.[26]

A randomised controlled trial of acute musculoskeletal pain in children found that the standard over-the-counter dose of ibuprofen gives greater pain relief than the standard dose of paracetamol.[27]

Adverse effects[edit] In recommended doses and for a limited course of treatment, the side effects of paracetamol are mild to non-existent.[28] However some risks and adverse correlations have been identified:

Liver damage[edit] Acute overdoses of paracetamol can cause potentially fatal liver damage. According to the US Food and Drug Administration, "Acetaminophen can cause serious liver damage if more than directed is used."[29] and in 2011 the FDA required manufacturers to update labels of all prescription combination acetaminophen products to warn of the potential risk for severe liver injury[30] and launched a public education program to help consumers avoid overdose.[31] [32] The risk may be heightened by chronic alcohol abuse. Paracetamol toxicity is the foremost cause of acute liver failure in the Western world, and accounts for most drug overdoses in the United States, the United Kingdom, Australia and New Zealand.[33][34][35][36] According to the FDA, in the United States there were "56,000 emergency room visits, 26,000 hospitalizations, and 458 deaths per year related to acetaminophen-associated overdoses during the 1990s. Within these estimates, unintentional acetaminophen overdose accounted for nearly 25 percent of the emergency department visits, 10 percent of the hospitalizations, and 25 percent of the deaths."[37]

Paracetamol is metabolised by the liver and is hepatotoxic; side effects are multiplied when combined with alcoholic drinks, and very likely in chronic alcoholics or patients with liver damage.[28][38] Some studies have suggested the possibility of a moderately increased risk of upper gastrointestinal complications such as stomach bleeding when high doses are taken chronically.[39] Kidney damage is seen in rare cases, most commonly in overdose.[40] The Food and Drug Administration has warned doctors against prescribing paracetamol/narcotic combinations whose dosages exceed 325 mg of paracetamol due to hepatoxicity risks of greater magnitude than the therapeutic benefits conferred.[41]

Cancer[edit] Chronic users of paracetamol may have a higher risk of developing blood cancer.[42]

Skin reactions[edit] On August 2, 2013, the U.S. Food and Drug Administration (FDA) issued a new warning about paracetamol. It stated that the drug could cause rare, and possibly fatal, skin reactions, such as Stevens–Johnson syndrome and toxic epidermal necrolysis. Prescription-strength products will be required to carry a warning label about skin reactions, and the FDA has urged manufacturers to do the same with over-the-counter products.[43]

Asthma[edit] There is an association between paracetamol use and asthma but it is unclear if it has a role in causing asthma.[44]

As of 2014, the American Academy of Pediatrics and the National Institute for Health and Clinical Excellence (NICE) continue to recommend paracetamol for pain and discomfort in children,[45][46][47][48][49][50] but some experts have recommended that paracetamol use by children with asthma, or at risk for asthma, should be avoided.[51][52]

Other factors[edit] In contrast to aspirin, paracetamol is not an antithrombotic, and thus may be used in patients where coagulation is a concern, and it does not cause gastric irritation.[53] However, paracetamol does not help reduce inflammation, while aspirin does.[54] Compared to ibuprofen—whose side effects may include diarrhea, vomiting and abdominal pain—paracetamol has fewer adverse gastrointestinal effects.[55]

Unlike aspirin, paracetamol is generally considered safe for children, as it is not associated with a risk of Reye's syndrome in children with viral illnesses.[56]

Paracetamol when taken recreationally with opioids may cause hearing loss.[57][better source needed]

Overdose[edit] Main article: Paracetamol toxicity Untreated paracetamol overdose results in a lengthy, painful illness. Signs and symptoms of paracetamol toxicity may initially be absent or non-specific symptoms. The first symptoms of overdose usually begin several hours after ingestion, with nausea, vomiting, sweating, and pain as acute liver failure starts.[58] People who take overdoses of paracetamol do not lose consciousness, although most people who attempt suicide with paracetamol wrongly believe that they will be rendered unconscious by the drug.[59] The process of dying from an overdose usually takes three to five days.

Paracetamol hepatotoxicity is, by far, the most common cause of acute liver failure in both the United States and the United Kingdom.[36][60] Paracetamol overdose results in more calls to poison control centers in the US than overdose of any other pharmacological substance.[61] Toxicity of paracetamol is believed to be due to its quinone metabolite.[62]

Untreated overdose can lead to liver failure and death within days. Treatment is aimed at removing the paracetamol from the body and replacing glutathione.[62] Activated charcoal can be used to decrease absorption of paracetamol if the patient presents for treatment soon after the overdose. While the antidote, acetylcysteine, (also called N-acetylcysteine or NAC) acts as a precursor for glutathione, helping the body regenerate enough to prevent or at least decrease the possible damage to the liver, a liver transplant is often required if damage to the liver becomes severe.[33][63] NAC was usually given following a treatment nomogram (one for patients with risk factors, and one for those without) but the use of the nomogram is no longer recommended as evidence to support the use of risk factors was poor and inconsistent, and many of the risk factors are imprecise and difficult to determine with sufficient certainty in clinical practice.[64] NAC also helps in neutralizing the imidoquinone metabolite of paracetamol.[62] Renal failure is also a possible side effect.

There were tablets available until 2004 (brand-name in the UK Paradote) that combined paracetamol with an antidote (methionine), to protect the liver in case of an overdose. One theoretical, but rarely if ever used, option in the United States is to request a compounding pharmacy to make a similar drug mix for at-risk patients.

In June 2009, a U.S. Food and Drug Administration (FDA) advisory committee recommended that new restrictions should be placed on paracetamol usage in the United States to help protect people from the potential toxic effects. The maximum dosage at any given time would be decreased from 1000 mg to 650 mg, while combinations of paracetamol and narcotic analgesics would be prohibited. Committee members were particularly concerned by the fact that the present maximum dosages of paracetamol had been shown to produce alterations in hepatic function.[65]

In January 2011, the FDA asked manufacturers of prescription combination products containing paracetamol to limit the amount of paracetamol to no more than 325 mg per tablet or capsule and began requiring manufacturers to update the labels of all prescription combination paracetamol products to warn of the potential risk of severe liver damage.[66][67][68][69] Manufacturers had three years to limit the amount of paracetamol in their prescription drug products to 325 mg per dosage unit.[67][69] In November 2011, the Medicines and Healthcare products Regulatory Agency revised UK dosing of liquid paracetamol for children.[70]

Pregnancy[edit] Experimental studies in animals and cohort studies in humans indicate no detectable increase in congenital malformations associated with paracetamol use during pregnancy.[71] Additionally, paracetamol does not affect the closure of the fetal ductus arteriosus as NSAIDs can.[72] However, paracetamol use by mother during pregnancy is associated with an increased risk of childhood asthma.[73]

Mechanism of action[edit]

AM404 – Metabolite of paracetamol

Anandamide – Endogenous cannabinoid To date, the mechanism of action of paracetamol is not completely understood. The main mechanism proposed is the inhibition of cyclooxygenase (COX), and recent findings suggest that it is highly selective for COX-2.[74] Because of its selectivity for COX-2 it does not significantly inhibit the production of the pro-clotting thromboxanes.[74] While it has analgesic and antipyretic properties comparable to those of aspirin or other NSAIDs, its peripheral anti-inflammatory activity is usually limited by several factors, one of which is the high level of peroxides present in inflammatory lesions. However, in some circumstances, even peripheral anti-inflammatory activity comparable to NSAIDs can be observed.

An article[75] in Nature Communications from researchers in London, UK and Lund, Sweden in November 2011 has found a hint to the analgesic mechanism of paracetamol, being that the metabolites of paracetamol e.g. NAPQI, act on TRPA1-receptors in the spinal cord to suppress the signal transduction from the superficial layers of the dorsal horn, to alleviate pain.

This conclusion has been contested in a new hypothesis paper[76] on how paracetamol might act. The author concedes that NAPQI is the active metabolite but that this reactive compound should react not only with the thiol in TRPA1 but also with any other suitably available nucleophile that it happens to encounter. It is suggested that thiol groups in cysteine proteases, e.g. the proteases that take part in the processing of procytokines, such as those generating IL-1β and IL-6, might be the targets giving rise to overall analgesic effects.

The COX family of enzymes are responsible for the metabolism of arachidonic acid to prostaglandin H2, an unstable molecule that is, in turn, converted to numerous other pro-inflammatory compounds. Classical anti-inflammatories such as the NSAIDs block this step. Only when appropriately oxidised is the COX enzyme highly active.[77][78] Paracetamol reduces the oxidised form of the COX enzyme, preventing it from forming pro-inflammatory chemicals.[79][80] This leads to a reduced amount of prostaglandin E2 in the CNS, thus lowering the hypothalamic set-point in the thermoregulatory centre.

Aspirin is known to inhibit the cyclooxygenase (COX) family of enzymes and, because paracetamol's action is partially similar to aspirin's,[clarification needed] much research has focused on whether paracetamol also inhibits COX. It is now clear that paracetamol acts via at least two pathways.[79][81][82][83]

The exact mechanisms by which COX is inhibited in various circumstances are still a subject of discussion. Because of differences in the activity of paracetamol, aspirin, and other NSAIDs, it has been postulated that further COX variants may exist. One theory holds that paracetamol works by inhibiting the COX-3 isoform—a COX-1 splice variant—of the COX family of enzymes.[74] When expressed in dogs, this enzyme shares a strong similarity to the other COX enzymes, produces pro-inflammatory chemicals, and is selectively inhibited by paracetamol.[84] However, some research has suggested that, in humans and mice, the COX-3 enzyme is without inflammatory action and paracetamol's blockage of it is not significant in its functioning in humans.[74][82]

Another possibility is that paracetamol blocks cyclooxygenase (as in aspirin), but that, in an inflammatory environment where the concentration of peroxides is high, the high oxidation state of paracetamol prevents its actions. This idea would mean that paracetamol has no direct effect at the site of inflammation, but instead acts in the CNS where the environment is not oxidative, to reduce temperature, etc.[84]

Paracetamol also modulates the endogenous cannabinoid system.[85] Paracetamol is metabolised to AM404, a compound with several actions; what is most important is that it inhibits the reuptake of the endogenous cannabinoid/vanilloid anandamide by neurons. Anandamide reuptake lowers synaptic levels of anandamide and results in more activation of the main pain receptor (nociceptor) of the body, the TRPV1 (older name: vanilloid receptor). By inhibiting anandamide reuptake, levels in the synapse remain high and are able to desensitise the TRPV1 receptor much like capsaicin. Furthermore, AM404 inhibits sodium channels, as do the anesthetics lidocaine and procaine.[86] Both of these actions by themselves have been shown to reduce pain, and are a possible mechanism for paracetamol. However, it has been demonstrated that, when cannabinoid receptors are blocked with synthetic antagonists, paracetamol's analgesic effects are prevented, suggesting its pain-relieving action involves the endogenous cannabinoid system.[87] Spinal TRPA1 receptors have also been demonstrated to mediate antinociceptive effects of paracetamol and Δ9-tetrahydrocannabinol in mice.[88]

Increase of social behavior in mice dosed with paracetamol (which corresponds to a reduction of social rejection response in humans) does not appear to be due to cannabinoid receptor type 1 activity. It may result from serotonin receptor agonism.[89]

Structure and reactivity[edit]

Paracetamol molecule polar surface area

Paracetamol Electron Map Electrostatic surface area Paracetamol consists of a benzene ring core, substituted by one hydroxyl group and the nitrogen atom of an amide group in the para (1,4) pattern.[90] The amide group is acetamide (ethanamide). It is an extensively conjugated system, as the lone pair on the hydroxyl oxygen, the benzene pi cloud, the nitrogen lone pair, the p orbital on the carbonyl carbon, and the lone pair on the carbonyl oxygen are all conjugated. The presence of two activating groups also make the benzene ring highly reactive toward electrophilic aromatic substitution. As the substituents are ortho, para-directing and para with respect to each other, all positions on the ring are more or less equally activated. The conjugation also greatly reduces the basicity of the oxygens and the nitrogen, while making the hydroxyl acidic through delocalisation of charge developed on the phenoxide anion.

Synthesis[edit] In a small-scale laboratory, paracetamol is prepared by a three-reaction sequence. First, nitration of phenol with sodium nitrate gives a mixture of two isomers, from which the wanted 4-nitrophenol (bp ~93 °C) can easily be separated by steam distillation. In this electrophilic aromatic substitution reaction, the phenol oxygen is strongly activating, thus the reaction requires only mild conditions as compared to nitration of benzene itself. The nitro group is then reduced to an amine, giving 4-aminophenol. This reaction can be accomplished using sodium borohydride. Finally, the amine is acetylated with acetic anhydride.[91] The industrial process is analogous, but hydrogenation is used instead of the sodium borohydride reduction.[92][93]

Synthesis of paracetamol from phenol.svg An alternative industrial synthesis developed by Hoechst–Celanese involves direct acylation of phenol with acetic anhydride catalyzed by HF, conversion of the ketone to a ketoxime with hydroxylamine, followed by the acid-catalyzed Beckmann rearrangement to give the amide.[93][94]

Celanese synthesis of paracetamol.png Demand for paracetamol in the United States was estimated at 30–35 thousand tonnes per year in 1997, equal to the demand from the rest of the world.[95]

Metabolism[edit]

Main pathways of paracetamol metabolism (click to enlarge). Pathways shown in blue and purple lead to non-toxic metabolites; the pathway in red leads to toxic NAPQI. Paracetamol is metabolised primarily in the liver, into toxic and non-toxic products. Three metabolic pathways are notable:[62]

Glucuronidation is believed to account for 40% to two-thirds of the metabolism of paracetamol.[96] Sulfation (sulfate conjugation) may account for 20–40%.[96] N-hydroxylation and dehydration, then GSH conjugation, accounts for less than 15%. The hepatic cytochrome P450 enzyme system metabolises paracetamol, forming a minor yet significant alkylating metabolite known as NAPQI (N-acetyl-p-benzoquinone imine)(also known as N-acetylimidoquinone).[62][97] NAPQI is then irreversibly conjugated with the sulfhydryl groups of glutathione.[97] All three pathways yield final products that are inactive, non-toxic, and eventually excreted by the kidneys. In the third pathway, however, the intermediate product NAPQI is toxic. NAPQI is primarily responsible for the toxic effects of paracetamol; this constitutes an example of toxication.

Production of NAPQI is due primarily to two isoenzymes of cytochrome P450: CYP2E1 and CYP1A2. The P450 gene is highly polymorphic, however, and individual differences in paracetamol toxicity are believed due to a third isoenzyme, CYP2D6. Genetic polymorphisms in CYP2D6 may contribute to significantly different rates of production of NAPQI. Furthermore, individuals can be classified as "extensive", "ultrarapid", "intermediate" and "poor" metabolisers (producers of NAPQI), depending on their levels of CYP2D6 expression. Although CYP2D6 metabolises paracetamol into NAPQI to a lesser extent than other P450 enzymes, its activity may contribute to paracetamol toxicity in extensive and ultrarapid metabolisers, and when paracetamol is taken at very large doses.[98] At usual doses, NAPQI is quickly detoxified by conjugation with glutathione.[62][97] Following overdose, and possibly also in extensive and ultrarapid metabolisers, this detoxification pathway becomes saturated, and, as a consequence, NAPQI accumulates causing liver and renal toxicity.[62]

Reactions[edit] 4-Aminophenol may be obtained by the amide hydrolysis of paracetamol. 4-Aminophenol prepared this way, and related to the commercially available Metol, has been used as a developer in photography by hobbyists.[99] This reaction is also used to determine paracetamol in urine samples: After hydrolysis with hydrochloric acid, 4-aminophenol reacts in ammonia solution with a phenol derivate, e.g. salicylic acid, to form an indophenol dye under oxidization by air.[100]

History[edit]

Julius Axelrod (pictured) and Bernard Brodie demonstrated that acetanilide and phenacetin are both metabolised to paracetamol, which is a better tolerated analgesic. Acetanilide was the first aniline derivative serendipitously found to possess analgesic as well as antipyretic properties, and was quickly introduced into medical practice under the name of Antifebrin by A. Cahn and P. Hepp in 1886.[101] But its unacceptable toxic effects, the most alarming being cyanosis due to methemoglobinemia, prompted the search for less toxic aniline derivatives.[81] Harmon Northrop Morse had already synthesised paracetamol at Johns Hopkins University via the reduction of p-nitrophenol with tin in glacial acetic acid in 1877,[102][103] but it was not until 1887 that clinical pharmacologist Joseph von Mering tried paracetamol on patients.[81] In 1893, von Mering published a paper reporting on the clinical results of paracetamol with phenacetin, another aniline derivative.[104] Von Mering claimed that, unlike phenacetin, paracetamol had a slight tendency to produce methemoglobinemia. Paracetamol was then quickly discarded in favor of phenacetin. The sales of phenacetin established Bayer as a leading pharmaceutical company.[105] Overshadowed in part by aspirin, introduced into medicine by Heinrich Dreser in 1899, phenacetin was popular for many decades, particularly in widely advertised over-the-counter "headache mixtures", usually containing phenacetin, an aminopyrine derivative of aspirin, caffeine, and sometimes a barbiturate.[81]

Von Mering's claims remained essentially unchallenged for half a century, until two teams of researchers from the United States analyzed the metabolism of acetanilide and paracetamol.[105] In 1947 David Lester and Leon Greenberg found strong evidence that paracetamol was a major metabolite of acetanilide in human blood, and in a subsequent study they reported that large doses of paracetamol given to albino rats did not cause methemoglobinemia.[106] In three papers published in the September 1948 issue of the Journal of Pharmacology and Experimental Therapeutics, Bernard Brodie, Julius Axelrod and Frederick Flinn confirmed using more specific methods that paracetamol was the major metabolite of acetanilide in human blood, and established that it was just as efficacious an analgesic as its precursor.[107][108][109] They also suggested that methemoglobinemia is produced in humans mainly by another metabolite, phenylhydroxylamine. A follow-up paper by Brodie and Axelrod in 1949 established that phenacetin was also metabolised to paracetamol.[110] This led to a "rediscovery" of paracetamol.[81] It has been suggested that contamination of paracetamol with 4-aminophenol, the substance von Mering synthesised it from, may be the cause for his spurious findings.[105]

Paracetamol was first marketed in the United States in 1950 under the name Triagesic, a combination of paracetamol, aspirin, and caffeine.[103] Reports in 1951 of three users stricken with the blood disease agranulocytosis led to its removal from the marketplace, and it took several years until it became clear that the disease was unconnected.[103] Paracetamol was marketed in 1953 by Sterling-Winthrop Co. as Panadol, available only by prescription, and promoted as preferable to aspirin since it was safe for children and people with ulcers.[103][105][111] In 1955, paracetamol was marketed as Children's Tylenol Elixir by McNeil Laboratories.[112] In 1956, 500 mg tablets of paracetamol went on sale in the United Kingdom under the trade name Panadol, produced by Frederick Stearns & Co, a subsidiary of Sterling Drug Inc. Panadol was originally available only by prescription, for the relief of pain and fever, and was advertised as being "gentle to the stomach," since other analgesic agents of the time contained aspirin, a known stomach irritant. In 1963, paracetamol was added to the British Pharmacopoeia, and has gained popularity since then as an analgesic agent with few side-effects and little interaction with other pharmaceutical agents.[103] Concerns about paracetamol's safety delayed its widespread acceptance until the 1970s, but in the 1980s paracetamol sales exceeded those of aspirin in many countries, including the United Kingdom. This was accompanied by the commercial demise of phenacetin, blamed as the cause of analgesic nephropathy and hematological toxicity.[81]

The U.S. patent on paracetamol has long expired, and generic versions of the drug are widely available under the Drug Price Competition and Patent Term Restoration Act of 1984, although certain Tylenol preparations were protected until 2007. U.S. patent 6,126,967 filed September 3, 1998 was granted for "Extended release acetaminophen particles".[113]

Available forms[edit] See also: List of paracetamol brand names

Tylenol 500 mg capsules

Panadol 500 mg tablets

For comparison: The pure drug is a white crystalline powder. Paracetamol is available in a tablet, capsule, liquid suspension, suppository, intravenous, intramuscular and Effervescent form. The common adult dose is 500 mg to 1000 mg. The recommended maximum daily dose, for adults, is 4000 mg. In recommended doses, paracetamol is generally safe for children and infants, as well as for adults,[114] although rare cases of acute liver injury have been linked to amounts lower than 2500 mg per day.[115]

In some formulations, paracetamol is combined with the opioid codeine, sometimes referred to as co-codamol (BAN). In the U.S., this combination is available only by prescription, while the lowest-strength preparation is over-the-counter in Canada, and, in other countries, other strengths may be available over the counter.[citation needed] Paracetamol is also combined with other opioids such as dihydrocodeine, referred to as co-dydramol (BAN), oxycodone or hydrocodone. Another very commonly used analgesic combination includes paracetamol in combination with propoxyphene napsylate. A combination of paracetamol, codeine, and the calmative doxylamine succinate is also available. The efficacy of paracetamol/codeine combinations have been questioned by recent research.[26]

Paracetamol is commonly used in multi-ingredient preparations for migraine headache, typically including butalbital and paracetamol with or without caffeine, and sometimes containing codeine.

Paracetamol is sometimes combined with phenylephrine hydrochloride.[116] Sometimes a third active ingredient, such as ascorbic acid,[116][117] caffeine,[118][119] chlorpheniramine maleate,[120] or guaifenesin.[121][122][123] is added to this combination.

Veterinary use[edit] Cats[edit] Paracetamol is extremely toxic to cats, which lack the necessary glucuronyl transferase enzymes to safely break it down. Initial symptoms include vomiting, salivation, and discolouration of the tongue and gums.

Unlike an overdose in humans, liver damage is rarely the cause of death; instead, methemoglobin formation and the production of Heinz bodies in red blood cells inhibit oxygen transport by the blood, causing asphyxiation (methemoglobemia and hemolytic anemia).[124]

Treatment with N-acetylcysteine,[125] methylene blue or both is sometimes effective after the ingestion of small doses of paracetamol.

Dogs[edit] Although paracetamol is believed to have no significant anti-inflammatory activity, it has been reported as effective as aspirin in the treatment of musculoskeletal pain in dogs.[126]

A paracetamol-codeine product (trade name Pardale-V)[127] licensed for use in dogs is available on veterinary prescription in the UK.[127] It should be administered to dogs only on veterinary advice and with extreme caution.[127]

The main effect of toxicity in dogs is liver damage, GI ulceration has been reported.[125][128][129][130] N-acetylcysteine treatment is efficacious in dogs when administered within a 2 hours of paracetamol ingestion.[125][126]

Snakes[edit] Paracetamol is also lethal to snakes, and has been suggested as a chemical control program for the invasive brown tree snake (Boiga irregularis) in Guam.[131][132] Doses of 80 mg are inserted into dead mice scattered by helicopter.[133]

Controversy[edit] In September 2013 an episode of This American Life entitled "Use Only as Directed"[134] highlighted deaths from acetominophen overdose. This report was followed by two reports by ProPublica[135][136] alleging that the "FDA has long been aware of studies showing the risks of acetaminophen. So has the maker of Tylenol, McNeil Consumer Healthcare, a division of Johnson & Johnson" and "McNeil, the maker of Tylenol, ... has repeatedly opposed safety warnings, dosage restrictions and other measures meant to safeguard users of the drug.".

A report prepared by an internal FDA working group describes a history of FDA initiatives designed to educate consumers about the risk of acetominophen overdose, and notes that one challenge to the Agency has been "identifying the appropriate message about the relative safety of acetaminophen, especially compared to other OTC pain relievers (e.g., aspirin and other NSAIDs)". The report notes that "Chronic use of NSAIDs is also associated with significant morbidity and mortality. NSAID gastrointestinal risk is substantial, with deaths and hospitalization estimated in one publication as 3200 and 32,000 per year respectively. Possible cardiovascular toxicity with chronic NSAID use has been a major discussion recently", finally noting that "The goal of the educational efforts is not to decrease appropriate acetaminophen use or encourage substitution of NSAID use, but rather to educate consumers so that they can avoid unnecessary health risks."[10]

Classification[edit] Paracetamol is part of the class of drugs known as "aniline analgesics"; it is the only such drug still in use today.[81] It is not considered an NSAID because it does not exhibit significant anti-inflammatory activity (it is a weak COX inhibitor).[137][138] This is despite the evidence that paracetamol and NSAIDs have some similar pharmacological activity.[139]

References[edit] Jump up ^ Granberg RA, Rasmuson AC (1999). "Solubility of paracetamol in pure solvents". Journal of Chemical & Engineering Data 44 (6): 1391–95. doi:10.1021/je990124v. Jump up ^ Karthikeyan, M.; Glen, R. C.; Bender, A. (2005). "General Melting Point Prediction Based on a Diverse Compound Data Set and Artificial Neural Networks". Journal of Chemical Information and Modeling 45 (3): 581–590. doi:10.1021/ci0500132. . edit Jump up ^ "melting point data for paracetamol". Lxsrv7.oru.edu. Retrieved 2011-03-19. Jump up ^ Aghababian, Richard V. (22 October 2010). Essentials of Emergency Medicine. Jones & Bartlett Publishers. p. 814. ISBN 978-1-4496-1846-9. Jump up ^ Ahmad, Jawad (17 October 2010). Hepatology and Transplant Hepatology: A Case Based Approach. Springer. p. 194. ISBN 978-1-4419-7085-5. ^ Jump up to: a b International Nonproprietary Names (INN) for Pharmaceutical Substances: Lists 1-96 of Proposed INN and lists 1-57 of Recommended INN, cumulative list N°12. World Health Organization. 2007. p. v. ISBN 9789240560253. Retrieved 20 January 2014. ^ Jump up to: a b c Macintyre, Pamela; Rowbotham, David; Walker, Suellen (26 September 2008). Clinical Pain Management Second Edition: Acute Pain. CRC Press. p. 85. ISBN 978-0-340-94009-9. Jump up ^ TGA Approved Terminology for Medicines, Section 1 – Chemical Substances (PDF). Therapeutic Goods Administration, Department of Health and Ageing,